This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Trovagene Schedules Release Of Third Quarter 2013 Financial Results And Hosts Investor Conference Call

SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter ended September 30, 2013 on Thursday, November 14, 2013 at 4:00 p.m. Eastern Standard Time ( 1:00 p.m. Pacific Standard Time).

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Trovagene's management team will host a conference call on Thursday, November 14, 2013 at 5:00 p.m. Eastern Standard Time ( 2:00 p.m. Pacific Standard Time) to discuss the results and update investors on the company's progress.

A live webcast of the call will be available online at www.trovagene.investorroom.com. To access the conference call, please dial (877) 870-4263 (domestic) or (412) 317-0790 (international); conference ID# 10036889.  To access the telephone replay of the call, dial (877) 344-7529 (domestic) or (412) 317-0088 (international), and Canada toll-free (855) 669-9657, replay ID# 10036889. The webcast and telephone replay will be archived on the company's website following the call. 

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Contact

Trovagene, Inc.     Amy Caterina   Investor Relations +1 (858) 952-7593     acaterina@trovagene.com    www.trovagene.com     



SOURCE Trovagene, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,095.72 +71.66 0.40%
S&P 500 2,117.44 +9.15 0.43%
NASDAQ 5,030.9260 +25.5350 0.51%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs